Search results for " Ep"

showing 10 items of 3258 documents

Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary fin…

2007

The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group I (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and C…

AdultMalemedicine.medical_specialtyIndomethacinPlaceboGastroenterologyElectrocardiographyPericarditisAcute pericarditisDouble-Blind MethodRecurrenceInternal medicineTroponin ImedicineHumansPericarditisRosuvastatinRosuvastatin CalciumPericarditis Colchicine Postpericardiotomy syndromeFirst episodeSulfonamidesmedicine.diagnostic_testbiologybusiness.industryAnti-Inflammatory Agents Non-SteroidalCardiovascular AgentsGeneral Medicinemedicine.diseaseSurgeryFluorobenzenesC-Reactive ProteinPyrimidinesTreatment OutcomeErythrocyte sedimentation rateAcute Diseasebiology.proteinDrug Therapy CombinationFemaleCreatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsbusinessFollow-Up Studiesmedicine.drugClinical Science
researchProduct

Medium chain acylcarnitines dominate the metabolite pattern in humans under moderate intensity exercise and support lipid oxidation.

2010

BACKGROUND: Exercise is an extreme physiological challenge for skeletal muscle energy metabolism and has notable health benefits. We aimed to identify and characterize metabolites, which are components of the regulatory network mediating the beneficial metabolic adaptation to exercise. METHODOLOGY AND PRINCIPAL FINDINGS: First, we investigated plasma from healthy human subjects who completed two independent running studies under moderate, predominantly aerobic conditions. Samples obtained prior to and immediately after running and then 3 and 24 h into the recovery phase were analyzed by a non-targeted (NT-) metabolomics approach applying liquid chromatography-qTOF-mass spectrometry. Under t…

AdultMalemedicine.medical_specialtyMagnetic Resonance SpectroscopyMetaboliteMuscle Fibers Skeletallcsh:MedicineBiologyIn Vitro TechniquesMass SpectrometryPhysiology/Muscle and Connective Tissuechemistry.chemical_compoundMiceMetabolomicsLipid oxidationInternal medicineCarnitinemedicineAnimalsHumansChemistry/BiochemistryCarnitineExercise physiologyMuscle Skeletallcsh:ScienceBeta oxidationExerciseCells CulturedChromatography High Pressure LiquidMultidisciplinaryReverse Transcriptase Polymerase Chain Reactionlcsh:RSkeletal muscleLipid metabolismLipid MetabolismDiabetes and EndocrinologyEndocrinologymedicine.anatomical_structurechemistryBiochemistry/Small Molecule ChemistryPublic Health and Epidemiology/Preventive Medicinelcsh:QPublic Health and Epidemiology/Exercise and SportsOxidation-Reductionmedicine.drugResearch ArticlePLoS ONE
researchProduct

Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey

2009

Background: Fabry disease is a rare X-linked lysosomal storage disorder characterised by severe multisystemic involvement that leads to major organ failure and premature death in affected men and women. Over the past 7 years, the Fabry Outcome Survey (FOS) has collected data on the natural history of Fabry disease, and the long-term efficacy and safety of enzyme-replacement therapy. This paper provides an update on the first analysis of FOS data. Design: Baseline data on clinical manifestations and causes of death in a cohort of 1453 patients (699 male, 754 female) from 19 countries worldwide were analysed. Causes of death of affected relatives were analysed separately. Results: The most fr…

AdultMalemedicine.medical_specialtyMetabolic disordersCardiomyopathyDisease030204 cardiovascular system & hematologyCohort Studies03 medical and health sciencesSex Factors0302 clinical medicineCause of DeathInternal medicineGeneticsmedicineHumansLipid disordersGenetic epidemiologyChildGenetics (clinical)Cause of deathChi-Square DistributionVascular diseasebusiness.industryData CollectionEnzyme replacement therapymedicine.diseaseFabry disease3. Good healthCohortFabry DiseaseFemaleKidney Diseasesbusiness030217 neurology & neurosurgeryCohort studyJournal of Medical Genetics
researchProduct

Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocar…

1994

Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i.v. on days 1, 29; mitomycin C 10 mg/m2 i.v. on day 1. This cycle was repeated every 8 weeks. Out of a total of 34 evaluable patients, 2 (5.8%) had a complete response and 7 (20.6%) had a partial response with an overall median duration of 40 weeks (range 20-128). The median survival of responding patients was not reached after a mean follow-up of 76 weeks, while that of patients with no change and progressive disease was reached at 36 and 13 weeks respectively. Treatment was generally well tolerated with h…

AdultMalemedicine.medical_specialtyMitomycinmedicine.medical_treatmentAdenocarcinomaGastric Adenocarcinoma Chemotherapy Epidoxorubicin Mitomicin CGastroenterologyStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedEpirubicinAged 80 and overPharmacologyChemotherapybusiness.industryStomachPalliative CareMitomycin CCombination chemotherapyMiddle Agedmedicine.diseaseConfidence intervalSurgeryInfectious Diseasesmedicine.anatomical_structureOncologyFluorouracilAdenocarcinomaFemaleFluorouracilbusinessProgressive diseasemedicine.drug
researchProduct

Is there a relationship between chocolate consumption and symptoms of depression? A cross-sectional survey of 13,626 US adults

2019

Objective: To examine associations between chocolate consumption and depressive symptoms in a large, representative sample of US adults. Methods: The data were from 13,626 adults (≥20 years) participating in the National Health and Nutrition Examination Survey between 2007–08 and 2013–14. Daily chocolate consumption was derived from two 24-hr dietary recalls. Depressive symptoms were assessed using the Patient Health Questionnaire (PHQ-9), with scores ≥10 indicating the presence of clinically relevant symptoms. We used multivariable logistic regression to test associations of chocolate consumption (no chocolate, non-dark chocolate, dark chocolate) and amount of chocolate consumption (grams/…

AdultMalemedicine.medical_specialtyNational Health and Nutrition Examination SurveyCross-sectional studyPopulationDark chocolatePatient Health QuestionnaireLogistic regressionDiet SurveysYoung AdultfoodEnvironmental healthEpidemiologymedicineHumansChocolateeducationLife StyleAgedAged 80 and overeducation.field_of_studybusiness.industryDepressionchocolate dark chocolate depressive symptoms epidemiology NHANESNHANES chocolate dark chocolate depressive symptoms epidemiologyMiddle Agedfood.foodUnited StatesPatient Health QuestionnairePsychiatry and Mental healthClinical PsychologyCross-Sectional StudiesLogistic ModelsQuartileJackson S. Smith L. Firth J. Grabovac I. Soysal P. Koyanagi A. Hu L. Stubbs B. Demurtas J. Veronese N. et al. -Is there a relationship between chocolate consumption and symptoms of depression? A cross-sectional survey of 13626 US adults.- Depression and anxiety cilt.36 ss.987-995 2019Femalebusiness
researchProduct

Mirtazapine compared with paroxetine in major depression.

2000

Background: The aim was to compare the efficacy and tolerability of mirtazapine with those of paroxetine. Method: 275 outpatients with a diagnosis of major depressive episode (DSM-IV) and a score ≥ 18 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17) were randomly assigned to 6 weeks of treatment with mirtazapine (15-45 mg/day) or paroxetine (20-40 mg/day). Efficacy was assessed by the HAM-D-17, Hamilton Rating Scale for Anxiety (HAM-A), and Clinical Global Impressions scales (Severity and Improvement), and analyses were performed on the intent-to-treat sample (127 mirtazapine-treated patients and 123 paroxetine-treated patients). Results: Mean daily doses were 32.7 mg of mirta…

AdultMalemedicine.medical_specialtyNauseaMirtazapineMirtazapineMianserinAntidepressive Agents TricyclicSeverity of Illness IndexDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineAmbulatory CareHumansPsychiatryMajor depressive episodeAgedPsychiatric Status Rating ScalesDepressive DisorderHamilton Rating Scale for DepressionMiddle AgedParoxetinePsychiatry and Mental healthParoxetineTreatment OutcomeTolerabilityAnxietyFemalemedicine.symptomPsychologymedicine.drugThe Journal of clinical psychiatry
researchProduct

BODY MASS INDEX DOES NOT CHANGE BEFORE PARKINSON'S DISEASE ONSET.

2008

Background and purpose:  Previous studies on the association between Parkinson’s disease (PD) and body mass index (BMI) have reported conflicting results. We investigated the relationship between PD and BMI by a case–control study. Methods:  PD patients were randomly matched to healthy individuals by sex and age. BMI distribution in cases has been compared with BMI of controls and odd ratios (ORs) with 95% CI were calculated. Results:  We included 318 PD patients and 318 controls. We observed no association between PD and BMI. BMI distribution in cases and controls was similar also when we adjusted for diabetes, hypercholesterolemia and the time elapsed between PD onset and the interview (O…

AdultMalemedicine.medical_specialtyParkinson's diseaseHypercholesterolemiaPopulationComorbidityWeight GainCoffeeBody Mass IndexRisk FactorsInternal medicineDiabetes mellitusWeight LossEpidemiologyDiabetes MellitusmedicineHumansObesityAge of OnseteducationAgedAged 80 and overHypertriglyceridemiaeducation.field_of_studybusiness.industrySmokingCase-control studynutritional and metabolic diseasesParkinson DiseaseMiddle AgedOverweightmedicine.diseaseNeurologyCase-Control StudiesHealthy individualsanthropometrical measures body mass index case–control study epidemiology Parkinson's disease risk factorsPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessBody mass index
researchProduct

Multifocal epithelial hyperplasia, a rare oral infection in Asia : report of twelve cases in Iran

2009

Objectives: Multifocal epithelial hyperplasia (MEH) is benign, asymptomatic oral disease with viral etiology. The frequency of this disease varies widely from one geographic region to another, and can vary, from 0.002 to 35% depending on the population studied. Study design: Here we report the clinicopathological features of twelve cases of MEH referred to Oral Medicine Department of Mashhad Dental School for the first time in Iran. Records of patients with the diagnosis of MEH in our department during 7 years were analyzed and data were extracted. Results: Most of the patients were younger than 20-year-old (66%), and females were predominantly affected (7:12). The mean age of onset was 12.…

AdultMalemedicine.medical_specialtyPathologyAdolescentOral infectionPopulationDiseaseIranBuccal mucosaAsymptomaticYoung AdultHumansMedicineEpithelial hyperplasiaChildeducationGeneral DentistryViral etiologyRetrospective Studieseducation.field_of_studybusiness.industry:CIENCIAS MÉDICAS [UNESCO]DermatologyOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASFocal Epithelial HyperplasiaFemaleSurgerymedicine.symptombusinessOral medicine
researchProduct

Clinically atypical spitzoid lesions: semi-quantitative histologic index correlation with dermoscopic scores (ABCD rule, 7-point checklist and patter…

2014

Background The distinction of Spitz and Reed nevi with atypical features from melanoma may be a difficult task. In these cases, the dermoscopic scores could bring variable results and not always correlate with the histologic diagnosis. Objective The aim of this study was to compare the histopathologic and dermoscopic findings in a cohort of clinically atypical Spitz and Reed nevi. Methods We retrospectively reviewed 19 cases of atypical Spitz and Reed nevi from our files. We constructed a new semi-quantitative histologic index (HI) based on the reproducible microscopic features, and correlated it with two dermoscopic scores: ABCD and 7-point checklist, as well as with the predominant dermos…

AdultMalemedicine.medical_specialtyPathologySkin NeoplasmsAdolescentPattern analysisDermoscopyDermatologyDiagnosis DifferentialCorrelationYoung AdultNevus Epithelioid and Spindle CellmedicineHumansNevusChildMelanomaRetrospective Studiesbusiness.industryRetrospective cohort studymedicine.diseaseDermatologyChecklistChecklistAbcd ruleInfectious DiseasesChild PreschoolFemalebusinessSemi quantitativeJournal of the European Academy of Dermatology and Venereology
researchProduct

Prevalence of tension-type headache in adult general population: the PACE study and review of the literature

2013

The mean global prevalence of tension-type headache (TTH) in adult is 42 %. To date, there have been no Italian studies on TTH prevalence in the adult general population. Therefore, we conducted a cross-sectional study, called PACE (PArma CEfalea, or "Headache in Parma"), aimed at detecting the prevalence and clinical features of primary headaches in the city of Parma's adult general population. Crude past-year prevalence for definite TTH was 19.4 % (95 % CI 16.8-21.9), namely 9.0 % (95 % CI 7.1-10.8) for infrequent TTH, 9.8 % (95 % CI 7.9-11.8) for frequent TTH, and 0.6 % (95 % CI 0.1-1) for chronic TTH. Crude prevalence for probable TTH was 2.3 % (95 % CI 1.3-3.3). Our study results indic…

AdultMalemedicine.medical_specialtyPediatricsCross-sectional studyPopulationPrevalenceDermatologyHeadache Tension-type headache Past-year prevalence Epidemiology ReviewLower limitAge DistributionPrimary headacheEpidemiologyPrevalencemedicineHumanseducationAgededucation.field_of_studybusiness.industryTension-Type HeadacheGeneral MedicineMiddle AgedPsychiatry and Mental healthCross-Sectional StudiesItalySettore MED/26 - NeurologiaFemaleAge distributionNeurology (clinical)businessNeurological Sciences
researchProduct